Glenmark Pharmaceuticals Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹587
- Today's High:
- ₹609.7
- Open Price:
- ₹606.2
- 52W Low:
- ₹344.429
- 52W High:
- ₹630
- Prev. Close:
- ₹607.4
- Volume:
- 1103281
Company Statistics
- Market Cap.:
- ₹166.92 billion
- Book Value:
- 335.777
- Revenue TTM:
- ₹133.07 billion
- Operating Margin TTM:
- 14.91%
- Gross Profit TTM:
- ₹77.57 billion
- Profit Margin:
- 2.23%
- Return on Assets TTM:
- 6.8%
- Return on Equity TTM:
- 3.92%
Company Profile
Glenmark Pharmaceuticals Limited had its IPO on under the ticker symbol GLENMARK.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Glenmark Pharmaceuticals Limited has a staff strength of 0 employees.
Stock update
Shares of Glenmark Pharmaceuticals Limited opened at ₹606.2 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of ₹587 - ₹609.7, and closed at ₹591.4.
This is a -2.63% slip from the previous day's closing price.
A total volume of 1,103,281 shares were traded at the close of the day’s session.
In the last one week, shares of Glenmark Pharmaceuticals Limited have slipped by -2.1%.
Glenmark Pharmaceuticals Limited's Key Ratios
Glenmark Pharmaceuticals Limited has a market cap of ₹166.92 billion, indicating a price to book ratio of 1.2951 and a price to sales ratio of 1.0219.
In the last 12-months Glenmark Pharmaceuticals Limited’s revenue was ₹133.07 billion with a gross profit of ₹77.57 billion and an EBITDA of ₹25.95 billion. The EBITDA ratio measures Glenmark Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Glenmark Pharmaceuticals Limited’s operating margin was 14.91% while its return on assets stood at 6.8% with a return of equity of 3.92%.
In Q1, Glenmark Pharmaceuticals Limited’s quarterly earnings growth was a positive 22.9% while revenue growth was a positive 12.6%.
Glenmark Pharmaceuticals Limited’s PE and PEG Ratio
- Forward PE
- 14.9031
- Trailing PE
- 56.1776
- PEG
Its diluted EPS in the last 12-months stands at ₹10.53 per share while it has a forward price to earnings multiple of 14.9031 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Glenmark Pharmaceuticals Limited’s profitability.
Glenmark Pharmaceuticals Limited stock is trading at a EV to sales ratio of 1.2553 and a EV to EBITDA ratio of 6.4809. Its price to sales ratio in the trailing 12-months stood at 1.0219.
Glenmark Pharmaceuticals Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0.42% and a payout ratio of 12.86%.
Balance sheet and cash flow metrics
- Total Assets
- ₹193.72 billion
- Total Liabilities
- ₹50.46 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 12.86%
Glenmark Pharmaceuticals Limited ended 2023 with ₹193.72 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹193.72 billion while shareholder equity stood at ₹94.74 billion.
Glenmark Pharmaceuticals Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹50.46 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹736.19 million in goodwill. Its cash balance stood at ₹14.43 billion and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹38.52 billion.
Glenmark Pharmaceuticals Limited’s total current assets stands at ₹98.74 billion while long-term investments were ₹0 and short-term investments were ₹2.01 billion. Its net receivables were ₹40.99 billion compared to accounts payable of ₹23.92 billion and inventory worth ₹29.78 billion.
In 2023, Glenmark Pharmaceuticals Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Glenmark Pharmaceuticals Limited paid ₹0.13 in dividends in 2023.
Other key metrics
- Current Trading Price
- ₹591.4
- 52-Week High
- ₹630
- 52-Week Low
- ₹344.429
- Analyst Target Price
- ₹
Glenmark Pharmaceuticals Limited stock is currently trading at ₹591.4 per share. It touched a 52-week high of ₹630 and a 52-week low of ₹630. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹517.4 and 200-day moving average was ₹434.75 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5323.4% of the company’s stock are held by insiders while 2046.3% are held by institutions.
Frequently Asked Questions About Glenmark Pharmaceuticals Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes GBR 310, a biosimilar candidate, which is in Phase 2 clinical trial for the treatment of asthma and chronic idiopathic urticaria; and GRC 39815, a retinoid-related orphan receptor gamma t (ROR”t) inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; GRC 17536, a targeting transient receptor potential ankyrin 1 inhibitor, which is in Phase 2 clinical trial for the treatment of diabetic peripheral neuropathy; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. The company’s pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, it offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.